Living donor liver re-transplantation for recurrent hepatoblastoma in the liver graft following complete eradication of peritoneal metastases under indocyanine green fluorescence imaging

Nobuhiro Takahashi, Yohei Yamada, Ken Hoshino, Miho Kawaida, Teizaburo Mori, Kiyotomo Abe, Takumi Fujimura, Kentaro Matsubara, Taizo Hibi, Masahiro Shinoda, Hideaki Obara, Kyohei Isshiki, Haruko Shima, Hiroyuki Shimada, Kaori Kameyama, Yasushi Fuchimoto, Yuukou Kitagawa, Tatsuo Kuroda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The curability of chemotherapy-resistant hepatoblastoma (HB) largely depends on the achievement of radical surgical resection. Navigation techniques utilizing indocyanine green (ICG) are a powerful tool for detecting small metastatic lesions. We herein report a patient who underwent a second living donor liver transplantation (LDLTx) for multiple recurrent HBs in the liver graft following metastasectomy for peritoneal dissemination with ICG navigation. The patient initially presented with ruptured HB at 6 years of age and underwent 3 liver resections followed by the first LDLTx with multiple sessions of chemotherapy at 11 years of age. His alpha-fetoprotein (AFP) level increased above the normal limit, and metastases were noted in the transplanted liver and peritoneum four years after the first LDLTx. The patient underwent metastasectomy of the peritoneally disseminated HBs with ICG navigation followed by the second LDLTx for multiple metastases in the transplanted liver. The patient has been recurrence-free with a normal AFP for 30 months since the second LDLTx. To our knowledge, this report is the first successful case of re-LDLTx for recurrent HBs. Re-LDLTx for recurrent HB can be performed in highly select patients, and ICG navigation is a powerful surgical tool for achieving tumor clearance.

Original languageEnglish
Article number730
JournalCancers
Volume11
Issue number5
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

Hepatoblastoma
Indocyanine Green
Living Donors
Optical Imaging
Liver Transplantation
Neoplasm Metastasis
Transplants
Metastasectomy
Liver
alpha-Fetoproteins
Drug Therapy
Peritoneum
Recurrence
Neoplasms

Keywords

  • Hepatoblastoma
  • Indocyanine green
  • Living donor liver transplantation
  • Transplant oncology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{f6bd40118e064e1f8a7f3b6645bfab5c,
title = "Living donor liver re-transplantation for recurrent hepatoblastoma in the liver graft following complete eradication of peritoneal metastases under indocyanine green fluorescence imaging",
abstract = "The curability of chemotherapy-resistant hepatoblastoma (HB) largely depends on the achievement of radical surgical resection. Navigation techniques utilizing indocyanine green (ICG) are a powerful tool for detecting small metastatic lesions. We herein report a patient who underwent a second living donor liver transplantation (LDLTx) for multiple recurrent HBs in the liver graft following metastasectomy for peritoneal dissemination with ICG navigation. The patient initially presented with ruptured HB at 6 years of age and underwent 3 liver resections followed by the first LDLTx with multiple sessions of chemotherapy at 11 years of age. His alpha-fetoprotein (AFP) level increased above the normal limit, and metastases were noted in the transplanted liver and peritoneum four years after the first LDLTx. The patient underwent metastasectomy of the peritoneally disseminated HBs with ICG navigation followed by the second LDLTx for multiple metastases in the transplanted liver. The patient has been recurrence-free with a normal AFP for 30 months since the second LDLTx. To our knowledge, this report is the first successful case of re-LDLTx for recurrent HBs. Re-LDLTx for recurrent HB can be performed in highly select patients, and ICG navigation is a powerful surgical tool for achieving tumor clearance.",
keywords = "Hepatoblastoma, Indocyanine green, Living donor liver transplantation, Transplant oncology",
author = "Nobuhiro Takahashi and Yohei Yamada and Ken Hoshino and Miho Kawaida and Teizaburo Mori and Kiyotomo Abe and Takumi Fujimura and Kentaro Matsubara and Taizo Hibi and Masahiro Shinoda and Hideaki Obara and Kyohei Isshiki and Haruko Shima and Hiroyuki Shimada and Kaori Kameyama and Yasushi Fuchimoto and Yuukou Kitagawa and Tatsuo Kuroda",
year = "2019",
month = "5",
day = "1",
doi = "10.3390/cancers11050730",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Living donor liver re-transplantation for recurrent hepatoblastoma in the liver graft following complete eradication of peritoneal metastases under indocyanine green fluorescence imaging

AU - Takahashi, Nobuhiro

AU - Yamada, Yohei

AU - Hoshino, Ken

AU - Kawaida, Miho

AU - Mori, Teizaburo

AU - Abe, Kiyotomo

AU - Fujimura, Takumi

AU - Matsubara, Kentaro

AU - Hibi, Taizo

AU - Shinoda, Masahiro

AU - Obara, Hideaki

AU - Isshiki, Kyohei

AU - Shima, Haruko

AU - Shimada, Hiroyuki

AU - Kameyama, Kaori

AU - Fuchimoto, Yasushi

AU - Kitagawa, Yuukou

AU - Kuroda, Tatsuo

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The curability of chemotherapy-resistant hepatoblastoma (HB) largely depends on the achievement of radical surgical resection. Navigation techniques utilizing indocyanine green (ICG) are a powerful tool for detecting small metastatic lesions. We herein report a patient who underwent a second living donor liver transplantation (LDLTx) for multiple recurrent HBs in the liver graft following metastasectomy for peritoneal dissemination with ICG navigation. The patient initially presented with ruptured HB at 6 years of age and underwent 3 liver resections followed by the first LDLTx with multiple sessions of chemotherapy at 11 years of age. His alpha-fetoprotein (AFP) level increased above the normal limit, and metastases were noted in the transplanted liver and peritoneum four years after the first LDLTx. The patient underwent metastasectomy of the peritoneally disseminated HBs with ICG navigation followed by the second LDLTx for multiple metastases in the transplanted liver. The patient has been recurrence-free with a normal AFP for 30 months since the second LDLTx. To our knowledge, this report is the first successful case of re-LDLTx for recurrent HBs. Re-LDLTx for recurrent HB can be performed in highly select patients, and ICG navigation is a powerful surgical tool for achieving tumor clearance.

AB - The curability of chemotherapy-resistant hepatoblastoma (HB) largely depends on the achievement of radical surgical resection. Navigation techniques utilizing indocyanine green (ICG) are a powerful tool for detecting small metastatic lesions. We herein report a patient who underwent a second living donor liver transplantation (LDLTx) for multiple recurrent HBs in the liver graft following metastasectomy for peritoneal dissemination with ICG navigation. The patient initially presented with ruptured HB at 6 years of age and underwent 3 liver resections followed by the first LDLTx with multiple sessions of chemotherapy at 11 years of age. His alpha-fetoprotein (AFP) level increased above the normal limit, and metastases were noted in the transplanted liver and peritoneum four years after the first LDLTx. The patient underwent metastasectomy of the peritoneally disseminated HBs with ICG navigation followed by the second LDLTx for multiple metastases in the transplanted liver. The patient has been recurrence-free with a normal AFP for 30 months since the second LDLTx. To our knowledge, this report is the first successful case of re-LDLTx for recurrent HBs. Re-LDLTx for recurrent HB can be performed in highly select patients, and ICG navigation is a powerful surgical tool for achieving tumor clearance.

KW - Hepatoblastoma

KW - Indocyanine green

KW - Living donor liver transplantation

KW - Transplant oncology

UR - http://www.scopus.com/inward/record.url?scp=85067105180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067105180&partnerID=8YFLogxK

U2 - 10.3390/cancers11050730

DO - 10.3390/cancers11050730

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 5

M1 - 730

ER -